Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medici... ( -- Recommendation based on study res...)

HOME >> MEDICINE >> TECHNOLOGY

Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency

Date:1/24/2008

-- Recommendation based on study results demonstrating survival advantage

of 18.4 months when added to standard therapy -- First study to show survival advantage over European standard of care

BOULDER, Colo., Jan. 24 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced that the European Medicines Agency (EMEA) has issued a positive opinion to recommend approval of Thalidomide Pharmion(R) for use in combination with melphalan and prednisone as first line treatment for patients with untreated multiple myeloma (MM), aged 65 years or older or ineligible for high dose chemotherapy. The marketing authorization application (MAA) for Thalidomide Pharmion was submitted to the EMEA in January 2007.

The EMEA's Committee for Medicinal Products for Human Use (CHMP) reviewed the application, and its positive opinion will be forwarded to the European Commission (EC), which generally follows, but is not obligated to follow, the recommendation of the CHMP, and issues final marketing approval within two to three months. Once ratified by the EC, a single marketing authorization would be granted to Pharmion to market Thalidomide Pharmion for first line multiple myeloma in the 27 member states of the European Union (EU) as well as Norway and Iceland.

"We are very pleased with this recommendation by the EMEA for the approval of Thalidomide in the treatment of first line multiple myeloma, and clearly appreciate that the return of Thalidomide to Europe as an approved therapy represents a significant step toward the safe distribution of this important and widely used drug for patients with multiple myeloma," said Patrick J. Mahaffy, Pharmion's president and chief executive officer. "This has been a lon
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
3. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
4. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
5. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
6. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
7. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
8. Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
9. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
11. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke

Post Your Comments:

(Date:5/23/2013)... 23, 2013 MedVantx, Inc., the company that has ... announced today the Company has completed a major expansion ... pharmaceutical products and the upgrade of its systems to ... in its specialty home delivery pharmacy in ... pharmaceutical manufacturers, physicians, health systems and payors novel distribution ...

(Date:5/23/2013)... 2013 BioLife Solutions , Inc. (OTC:BLFS), a ... hypothermic storage and cryopreservation freeze ... media manufacturer , today announced its participation at the ... 2013 this week in London ... Dr. Aby J. Mathew, BioLife,s Senior Vice President and ...

(Date:5/23/2013)... TOKIO , 22. Mai 2013 ... Weiteren Ranbaxy), eine Tochtergesellschaft von Daiichi ... Sankyo), gab am 22. Mai die ... letzten Jahren ergriffen hat, um sich ... ( http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html ). ...

Breaking Medicine Technology:MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2 MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3 Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an 2

[0] MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy [0] BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress [0] Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an

... 2011 Reportlinker.com announces that ... is available in its catalogue: ... Acid Testing Market--New Product Development ... For Instrument and Reagent Suppliers ...

... NEW YORK, June 20, 2011 Reportlinker.com ... is available in its catalogue: ... 2011 http://www.reportlinker.com/p0558499/Top-Medical-Devices-and-Imaging-Technologies-2011.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Devices ... medical device and imaging technologies that have ...

Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers Reportlinker Adds Top Medical Devices and Imaging Technologies 2011

(Date:5/23/2013)... (PRWEB) May 23, 2013 NDI ... funds and develops innovative neurodevice technologies, has launched ... (DBI). DBI will commercialize its groundbreaking technology ... (DBS) therapy for patients with Parkinson’s disease. ... Parkinson’s disease and generates more than $275 million ...

(Date:5/23/2013)... little was scientifically known about the human potential to ... people who are suffering in a way that motivates ... at the Center for Investigating Healthy Minds at the ... adults can be trained to be more compassionate. The ... Science , is the first to investigate whether training ...

(Date:5/23/2013)... connections in the brains of people affected by ... Peter Williamson, from Western University, to gain a ... important diseases. Dr. Williamson and colleagues have ... are disrupted in different psychiatric diseases. These ... Meeting, the annual meeting of the Canadian Association ...

(Date:5/23/2013)... DRE, Inc. is now offering the DRE ... upgrade older model DRE or BFW halogen headlights to ... , DRE and BFW customers can easily and affordably ... to LED with DRE’s American-made Xavier-C3 LED headlight conversion ... a bright, clean and even field of illumination with ...

(Date:5/23/2013)... MA (PRWEB) May 23, 2013 ... to announce the launch of Current Digital, a ... web development and digital marketing needs. Companies now ... a strategic business necessity. This can often leave ... creative strategy on preselected software platforms that they ...

Breaking Medicine News(10 mins):Health News:NDI Launches Deep Brain Innovations, LLC 2 Health News:NDI Launches Deep Brain Innovations, LLC 3 Health News:Study shows people can be trained to be more compassionate 2 Health News:Study shows people can be trained to be more compassionate 3 Health News:Study shows people can be trained to be more compassionate 4 Health News:Researchers identify networks of neurons in the brain that are disrupted in psychiatric disease 2 Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 2 Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 3 Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 2 Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 3

[0] NDI Launches Deep Brain Innovations, LLC [0] Study shows people can be trained to be more compassionate [0] Researchers identify networks of neurons in the brain that are disrupted in psychiatric disease [0] New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems [0] Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies

... in French . ,OTTAWA (June ... Health, announced today that the Government of Canada is ... principal medical isotope affected by the current shutdown at ... isotopes in combination with imaging technologies to diagnose and ...

... Extending health insurance coverage to all children in the ... benefits that are greater than the costs, according to ... Public Policy. "Providing health insurance to all children ... Ho, chair in health economics at the Baker Institute ...

... Association for Molecular Pathology (AMP) today released the text ... Federal Coordinating Council for Comparative Effectiveness Research (CER) in ... on which to focus CER activities. "CER is ... makers who see it as a method to examine ...

... season will soon arrive in the Asian territories and culicine ... the virus that causes Japanese Encephalitis (JE), which kills 10-15,000 ... the largest provider of travel medical services in the U.S. ... FDA, and is ready for distribution in the United States. ...

... (Nasdaq: BMRN ) announced today that the temporary ... is not expected to have any impact on Aldurazyme supply ... fill at the Allston Landing facility was in September 2008. ... vialed inventory on hand, utilizes a second fill finish supplier ...

... CRYSTAL, Minn., June 16 On June 4, 2009, Herzing University ... to begin a Bachelor of Science in Nursing ... of preparation. , , A new medical lab, extensive ... few of the additions brought to campus to prepare for the ...

Cached Medicine News:Health News:Providing health insurance for US children would be cheaper than expected, study says 2 Health News:AMP urges inclusion of molecular diagnostic tests in comparative effectiveness research 2 Health News:AMP urges inclusion of molecular diagnostic tests in comparative effectiveness research 3 Health News:Monsoon Season will Bring Japanese Encephalitis 2 Health News:Temporary Production Interruption at Allston Landing Manufacturing Facility Has No Impact on Aldurazyme 2 Health News:Herzing University, Minneapolis Receives Board of Nursing Approval 2

Government of Canada supports research to help address medical isotope shortage Providing health insurance for US children would be cheaper than expected, study says AMP urges inclusion of molecular diagnostic tests in comparative effectiveness research Monsoon Season will Bring Japanese Encephalitis Temporary Production Interruption at Allston Landing Manufacturing Facility Has No Impact on Aldurazyme Herzing University, Minneapolis Receives Board of Nursing Approval

At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....

Colorado Microneedles offer the surgeon precision in cutting and coagulation, without the expense and inconvenience of a laser. The needles may also be used for dissecting large areas such as the sca...

Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...

Medicine Products:

Webster Ruler Colorado Needle Sinuscope. A4.0AE70 Sinuscope. A1.8AE70